CW

Analyst Note: Curtiss-Wright Corporation (CW)

Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

• Setup State: Actionable (Contextual)
• Coil Classification: FORMING
• Conservative Entry: — (Pending breakout confirmation)
• Breakout Level: — (Not defined in current data)
• Current Price: $771.93
• Extension: — (Not applicable as breakout has not fired)
• ATR Context: Current ATR is 3.3% (Productive). This sits within the historical "sweet spot" (4-6% is ideal, but 3.3% indicates healthy, non-extreme volatility suitable for position sizing).

2. Thesis Layer

CW is a primary beneficiary of the U.S. Navy's acceleration in submarine and surface ship programs. The company's role is critical in providing propulsion and auxiliary equipment for the Virginia-class and Columbia-class submarine programs, as well as the Ford-class aircraft carrier program.

• Primary Secular Thesis: Defense Modernization → Naval / Shipbuilding
• Directness: Tier Direct.
• Confidence: High.
• Thesis Analysis:
• Evidence of Direct Exposure: Management explicitly cited "increased demand for EM actuation equipment supporting ground-based mobile launcher systems" and "continued strong demand for nuclear propulsion equipment" (E5, E6).
• Order Book Visibility: The order book reached a record $4.3 billion (E2), with new orders in the Naval & Power segment up 16% to $1.2 billion in Q1 2026 (E8).
• Additional Tailwinds: The company is also positioned in Commercial Nuclear (Power & Process), benefiting from the transition of advanced reactors from development to prototype stages and the maintenance of existing reactors (E7, E13). This provides a dual-engine growth profile: defense (high margin, long duration) and commercial nuclear (high growth, regulatory tailwinds).

3. The Business

• Business Model: Curtiss-Wright is a global integrated business providing highly engineered products, solutions, and services to Aerospace & Defense (A&D) markets and critical technologies in commercial power, process, and industrial markets.
• Industry: Industrials / Defense Electronics / Nuclear Power Equipment.
• Operational Highlights (as of 2026-06-13):
• Revenue Mix: Approximately 70% of 2026 revenues are expected to be generated from A&D-related markets (E11). U.S. Government contracts represented 58% of total net sales in 2025 (E17).
• Segment Performance (Q1 2026):
• Naval Defense: Sales increased $35 million (21% YoY) to $402 million, driven by production timing on Virginia/Columbia-class submarines and aftermarket fleet services (E12).
• Power & Process: Sales increased $25 million, driven by commercial nuclear products for existing reactor maintenance and next-gen advanced reactor prototypes (E13).
• Operating Margin: Expanded 150 basis points to 17.5% in Q1 2026, reflecting strong operational leverage (E14).
• Order Book: New orders increased 16% YoY to $1.2 billion in Q1 2026 (E8). The full-year order book is at a record $4.3 billion (E2).
• Guidance (Management Expectations):
• Sales: Management expects overall sales to increase 7% to 8% for full-year 2026 (E1).
• EPS: Full-year 2026 diluted EPS guidance is raised to a range of $14.90 to $15.30, representing 13% to 16% growth (E3).
• Free Cash Flow: Guidance raised to reflect higher confidence in the full-year outlook (E4).
• Power & Process: Expecting mid-to-high teens growth in sales for the segment (E7).

4. Archetype and Conviction

• Archetype: Quality Compounder
• Fit: The company demonstrates consistent margin expansion (17.5% operating margin), strong free cash flow conversion, and a record order book that provides high visibility. The business model is asset-light in terms of R&D risk (highly engineered, proprietary tech) and capital-intensive in terms of manufacturing, but the backlog ensures revenue stability.
• Valuation & Financial Spine:
• Forward consensus EPS (FY1) is $15.23, and FY2 is $17.07 (E35).
• The current price of $771.93 implies a forward P/E of approximately 50.7x (FY1) and 45.2x (FY2). While this is a premium valuation, it is consistent with a "Quality Compounder" in a high-growth, high-visibility secular theme (Defense/Nuclear) where management has raised guidance and margins are expanding.
• Conviction Stack:
• Thesis Strength: High. The defense modernization and nuclear renaissance are structural, multi-year trends.
• Evidence Quality: High. Multiple primary sources (earnings transcripts, 10-K/10-Q filings) confirm record orders, margin expansion, and raised guidance.
• Rerating Potential: Moderate to High. If the "Quality Compounder" narrative holds and the order book continues to grow, the market may re-rate the stock from a standard industrial multiple to a high-growth defense/nuclear multiple.

5. Invalidations, Strengths, and Gaps

• What Would Invalidate:
• A significant reduction in the order book or a cut in full-year guidance (currently raised to $14.90-$15.30 EPS).
• A contraction in operating margins below 17.5% (Q1 2026 level).
• What Would Strengthen:
• Further increases in the order book or guidance for 2027.
• Continued margin expansion beyond 17.5%.
• Gaps in Evidence:
• ATR at Breakout: The structural quality ATR at the moment of breakout is not yet recorded.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: High Key evidence: Record $4.3B order book providing high visibility; Q1 2026 operating margin expanded 150bps to 17.5%; Management raised full-year EPS guidance to $14.90-$15.30 (13-16% growth). Key risks: Valuation compression if growth slows; potential supply chain disruptions in defense manufacturing; geopolitical shifts affecting defense spending. Expected path: Management expects continued strong conversion and sales growth driven by naval defense and commercial nuclear; price likely consolidates to build the breakout structure before advancing. Expected horizon: 6 to 12 months for the thesis to fully play out as order book converts to revenue.